Fig. 3: Neutralizing antibody responses against multiple SARS-CoV-2 variants. | Nature Communications

Fig. 3: Neutralizing antibody responses against multiple SARS-CoV-2 variants.

From: Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern

Fig. 3

a Results of 50% pseudovirus neutralization titer (pVNT50) in 470 vaccine recipients on day 28 after the second dose against multiple SARS-CoV-2 variants, including Alpha (p < 0.0001), Beta (p < 0.0001), Gamma (p < 0.0001), and Iota (p < 0.0001) variants compared with the wild-type strain. b Results of 50% pseudovirus neutralization titer (pVNT50) in 220 vaccine recipients on day 180 after the second dose against Delta (p < 0.0001) compared the wild-type strain. c Results of 50% pseudovirus neutralization titer (pVNT50) in 16 convalescent COVID-19 patients against multiple SARS-CoV-2 variants, including Alpha (p = 0.0151), Beta (p = 0.0005), Gamma (p = 0.0034), Delta (p = 0.0054), and Iota (p = 0.0151) variants compared with the wild-type strain. Each vertical bar represents the geometric mean with the 95% confidence interval (95% CI). The fold-changes in geometric mean titer are shown above. The horizontal dashed line represents the lower limit of detection of the assay (>4). The exact p values (two-sided) were calculated using the Wilcoxon matched-pairs signed-rank test. No adjustment was done for multiple comparison. Source data are provided as a Source data file.

Back to article page